The global anticoagulants market size is projected to reach 45.50 billion by the end of 2026. According to a report published by Fortune Business Insights, titled “Anticoagulants Market Size, Share & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026,” the market was worth USD 21.45 billion in 2018 and will exhibit a CAGR of 9.9% during the forecast period,2019-2026.

visit: https://www.fortunebusinessinsights.com/industry-reports/anticoagulants-market-101807

Some of the leading companies that are operating in the global market are:

• Bristol-Myers Squibb Company
• Pfizer Inc.
• Bayer AG
• Janssen Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Other Prominent Players

Anticoagulants are widely used across the healthcare industry for the treatment of several cardiovascular and health-related disorders. They are effectively used to treat blood clots avoid blockage of blood flow that is caused due to these drugs. The demand for anticoagulants has risen dramatically in recent years, owing to its exceptional properties. Anticoagulants are included in major drugs that are prescribed for the treatment of cardiovascular diseases. The properties of anticoagulants have led to a high product adoption in diverse industries. The increasing emphasis on the severe effects of unattended cardiovascular diseases will fuel the demand for anticoagulants.

North America to Emerge Dominant; High Prevalence of Cardiovascular Disease to Create Several Growth Opportunities

The market is segmented on the basis of regional demographics into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among these regions, North America will emerge dominant in the coming years. The high prevalence of cardiovascular disease, coupled with the increasing emphasis on the research and development of new drugs will open up a huge potential for the companies operating in the market in this market. As of 2018, the market in North America was worth USD 10.10 billion. Besides North America, Europe will witness significant growth in the coming years, owing to the high incidence of deaths caused due to cardiovascular disease in several countries across this region. The high demand for anticoagulants in emerging countries such as Germany, France, and UK will have a positive influence on the growth of the market in this region.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/e-prescribing-market-102698

https://www.fortunebusinessinsights.com/industry-reports/veterinary-animal-vaccines-market-101534

The global E-prescribing market size is projected to reach USD 4,017.79 million by 2026 owing to the implementation of e-prescribing software in the electronic health record solutions that simplified prescription filling over the years. E-prescribing or electronic prescribing is a technology substructure that allows physicians and medical practitioners to send computer-based electronically generated prescriptions to a hospital-based or standalone pharmacy. It is also cost-efficient and reduces the chances of medication errors by pharmacists.

visit:  https://www.fortunebusinessinsights.com/e-prescribing-market-102698

The market is discussed in details in a recently published report by Fortune Business Insights™ titled, “E-prescribing Market Size, Share & Industry Analysis, By Delivery Mode (Web-based, On-premise), By Prescription Type (Controlled substance, Non controlled Substances) By End User (Hospitals, Physician’s offices, Pharmacies) and Regional Forecast, 2019-2026.” As per this report, the market value was USD 863.64 million in 2018 and is expected to rise at a CAGR of 21.0 % in the forecast duration set between 2019 to 2026.

What are the Report Highlights?

The report is based on an in-depth analysis of the market and provides a 360-degree overview of the same. It throws light on significant industry developments, current e-prescribing market trends, and other interesting insights into the market. It discusses factors boosting, repelling, challenging, ad creating opportunities for the market during the forecast period. The report also describes the table of segmentation in detail and mentions the names and figures of the leading segments with their attributed factors. For more information on the report, log on to the company website.

Market Drivers

Better Medical Record-Keeping Factor with Electronic-Prescription Solutions to Add Impetus to Market

The increasing adoption of e-prescription based electronic health record (EHR) solutions on a global basis is the key factor boosting the e-prescription market growth. Besides this, electronic prescription system offers better medical history records than handwritten prescriptions. It cannot be forged or exploited, thereby adding to the growth of the market in the forthcoming years. Additionally, rising initiatives taken by both public and private healthcare organizations to integrate e prescribing solutions and eliminate the use of adverse drug events (ADEs) and medical errors will also help to aid in the expansion of the market in the forecast period.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/wound-care-market-103268

https://www.fortunebusinessinsights.com/sleep-apnea-treatment-devices-market-102694

The global prefilled syringes market size is projected to reach USD 9.53 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. Rising incidence of cancer and other Non-Communicable Diseases (NCDs) is expected to be the primary factor fueling the prefilled syringe market growth. According to the World Health Organization (WHO), 9 million deaths are caused by cancer worldwide every year. In total, NCDs cause close to 41 million deaths, or 71% of the global deaths, annually, states the WHO.

visit: https://www.fortunebusinessinsights.com/industry-reports/prefilled-syringes-market-101946

The National Cancer Institute estimates that in the US alone, 1,735,530 new cancer cases were reported in 2018; by 2030, this figure is anticipated to reach 23.6 million. Such widespread prevalence of cancer and other NCDs has generated the need for alternative solutions such as biological drugs. The administration of these drugs requires modern devices such as prefilled syringes, which is foreseen to augment the prefilled syringes market potential in the forthcoming years.

Fortune Business Insights™ provides the above information in its new report, titled “Prefilled Syringes Market Size, Share & Industry Analysis, By Material (Glass and Plastic) By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System) By Product (Complete Syringe Set and Components & Accessories) By Design (Double-chamber, Multiple-chamber, and Single-chamber) By End-user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others) and Regional Forecast, 2019-2026

Europe to Lead the Pack; Asia-Pacific to Grow at a Remarkable Pace

Among regions, Europe is slated to dominate the prefilled syringes market share during the forecast period, with the region’s market size having stood at USD 1.76 billion in 2018. Factors propelling the market in Europe include growing uptake of self-injectable drug devices and increasing preference for biological drugs for treating chronic diseases.

Asia-Pacific is forecasted to showcase high-paced growth on account of increasing prevalence of chronic diseases and a speedily growing patient population. North America is projected to hold the second-largest section of the prefilled syringe market share owing to a strong presence of major market players and rising incidence of cancer.

Product Diversification to be the Focus Area for Competitors

Key players are putting in place different measures to gain a competitive edge, according to the prefilled syringes market analysis. While some companies are looking for ways to widen their product offerings, other participants are engaging in merger and acquisition activities to expand their presence in the market.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/industry-reports/diabetes-devices-market-100805

https://www.fortunebusinessinsights.com/industry-reports/veterinary-animal-vaccines-market-101533

The global insulin pump market is likely to gain impetus from the ever-increasing prevalence of diabetes reported worldwide. Coupled with this, the rising geriatric population and surging number of people affected by type 1 diabetes would drive the market growth. Fortune Business Insights™ provided this information in a recent report, titled, “Insulin Pump Market Size, Share & Industry Analysis, By Product Type (Pumps (Tethered Pumps, Patch Pumps, and Others), and Consumables), By Disease Indication (Type 1 Diabetes and Type 2 Diabetes), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Stores), and Regional Forecast, 2020-2027.” The report further states that the insulin pump market size was USD 4.15 billion in 2019 and is projected to reach USD 8.50 billion by 2027, exhibiting a CAGR of 9.4% during the forecast period.

Please visit: https://www.fortunebusinessinsights.com/insulin-pump-market-102735

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

Type 2 Diabetes Segment to Grow Remarkably Backed by New Product Launches

In terms of disease indication, the market is bifurcated into type 1 diabetes and type 2 diabetes. Out of these, the type 1 diabetes segment is expected to procure the maximum insulin pumps market share in the coming years. This growth is attributable to the increasing usage of insulin pumps amongst these patients, unlike those living with type 2 diabetes. The Centers of Disease Control and Prevention stated that in 2018, around 1.4 million adults belonging to the age group of 20 years and above living in the U.S. with type 1 diabetes used insulin. But, the type 2 diabetes segment would also showcase a remarkable growth because of the presence of favorable health reimbursement and rising number of novel product launche

Government Initiatives to Reduce Cost Burdenwill Favor Growth in North America

Based on geography, the market is classified into the Middle East and Africa, Europe, North America, Asia Pacific, and Latin America. Out of these, in 2019, North America generated USD 2.11 billion in terms of insulin pumps and consumables market revenue. Rising number of innovative product launches and high demand for drug delivery devices are the major factors that would drive the market growth in this region. Also, active support of the government of various countries in this region to lower the cost burden of diabetes by supplying patients with insulin pump covered by Medicare would propel market growth.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/cosmeceuticals-market-102521

https://www.fortunebusinessinsights.com/drug-delivery-market-102416

The global sleep apnea treatment devices market size is set to touch USD 8.97 billion by 2026, exhibiting a CAGR of 8.2% during the forecast period. Steadily climbing demand for sleep apnea devices, stemming from a consistent spread in the prevalence of sleep apnea, will be a major growth driver for this market, shares Fortune Business Insights™ in its new report, titled “Sleep Apnea Treatment Devices Market Size, Share & Industry Analysis, By Device Type (Positive Airway Pressure (PAP) Devices, Oral Appliances, Masks & Accessories, and Others), By End User (Sleep Laboratories & Clinics, and Homecare & Other Settings), and Regional Forecast, 2019-2026.

visit: https://www.fortunebusinessinsights.com/sleep-apnea-treatment-devices-market-102694

A study published in the medical journal Lancet in 2019 found that nearly 1 billion people worldwide suffer from Obstructive Sleep Apnea (OSA). Regionally, too, the statistics conform to the global trends. For instance, the European Respiratory Society estimates that 13% to 32% of the geriatric population in Europe suffer from sleep apnea. As a result, the demand for sleep apnea treatment is escalating and driving the sleep apnea treatment devices market trends. Furthermore, the incidence of OSA is spiking owing to the rising prevalence of obesity, the most common cause for interrupted sleep, which according to the World Health Organization, presently affects close to 650 million adults worldwide.

Availability of Advanced Treatment Options to Propel the Market in North America

With a market size of USD 2.35 billion in 2018, North America is poised to dominate the sleep apnea treatment devices market share during the forecast period. The key factors augmenting this regional market include wide availability and high adoption of advanced products, along with growing prevalence of sleep disorders among the populace. In addition to this, supportive health insurance and reimbursement policies are further fueling the uptake of these devices in the region.

In Asia-Pacific, the major driving force for the market is the rising demand for sleep apnea therapies in Japan and the presence of a large, underpenetrated market in the rest of the region. These factors are expected to aid Asia-Pacific to register a considerable CAGR in the upcoming years.

Innovative Product Offerings to Characterize Market Competition

Key players in this market are focusing on consolidating their position, according to the sleep apnea treatment devices market report. These companies aim to entrench themselves in this market through frequent launch of innovative products, which also helps them diversify their portfolio of offerings to consumers.

Industry Developments:

• April 2019: San Diego-based medical devices manufacturer ResMed launched its novel top-of-head, sleep apnea solution called the AirFit P30i. The mask features a tube-up mechanism that enables the patient to sleep in any position without causing any discomfort.
• September 2019: Koninklijke Philips N.V., commercially introduced its sleep position therapy product for Positional Obstructive Sleep Apnea (POSA) patients, the Philips NightBalance. This is the company’s clinically-verified alternative to mask-based treatments for OSA, which also provides doctors and patients with real-time data.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/industry-reports/prefilled-syringes-market-101946

https://www.fortunebusinessinsights.com/industry-reports/pet-insurance-market-101956

The global ophthalmic surgical devices market size is anticipated to reach USD 12.75 billion by 2026, registering a CAGR of 4.8% during the forecast period. Rising prevalence of cataract is one of the key factors fueling this market. The World Health Organization (WHO) defines cataract as “clouding of the lens of the eye which impedes the passage of light”. The WHO estimates that currently there are approximately 18 million around the world that are blind in both eyes due either to improper surgery or inaccessibility to advanced procedures.

While this eye condition mostly occurs as a person ages, the WHO claims that other risk factors such as diabetes, exposure to UV light, and smoking are fast emerging as major grounds for cataract. Moreover, the International Agency for the Prevention of Blindness (IAPB) states that blindness from cataract is around 5% in developed countries and 50% in developing and underdeveloped nations. Increasing demand for ocular treatments from emerging economies is, therefore, expected to lead the ophthalmic surgical devices market trends in the upcoming decade.

visit:

https://www.fortunebusinessinsights.com/ophthalmic-surgical-devices-market-102054

Major Companies Profiled in the Ophthalmic Surgical Devices Market Report:

• Oertli Instrumente AG
• Allergan
• Hoya Corporation
• Bausch & Lomb Incorporated
• Johnson and Johnson Services, Inc.
• New World Medical, Inc.
• Glaukos
• STAAR SURGICAL
• ZEISS International
• Alcon (Part of Novartis AG)

Patient-friendly Healthcare Policies to Propel the Market in North America

North America is predicted to dominate the ophthalmic surgical devices market share over the forecast period, having generated a revenue of USD 2.82 billion in 2018. The most favorable factor for the market here is the convenient nature of healthcare policies. Apart from this, increasing prevalence of cataract, glaucoma, and refractive errors, along with strong presence of other risk factors such as smoking and diabetes, will also further the growth of the market in North America.

Asia-Pacific is expected to significantly contribute to the ophthalmic surgical instrument market revenue owing to the rising number of aging people in China and Japan and growing incidence of ocular disorders. In Europe, the market will be driven by active adoption of advanced diagnostic and surgical procedures.

Interesting New Product Launches to Fire up Competitive Spirits

The ophthalmology surgical devices market analysis points towards a period of fierce competition in this market as key players introduce novel products to strengthen their hold on the market. Additional encouragement is being provided by timely regulatory approvals to innovative offerings.

According to the World Bank, approximately 84% populace in Germany depend on Internet and around 75% populace in the U.S. are subscribers of the Internet, which augments the global ePharmacy market growth. Fortune Business Insights states that the global ePharmacy market is projected to reach US$ 177,794.9 Mn by 2026, thereby exhibiting an impressive CAGR of 17.3% during the forecast period (2019-2026). The company further states that the global market was valued at US$ 49,727.7 Mn in 2018. According to a published report by Fortune Business Insights, titled, “ePharmacy: Global Market Analysis, Insights and Forecast, 2019-2026,” the global ePharmacy market will witness notable growth during the forecast period due to the technological advancements based on artificial intelligence.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/epharmacy-market-100238

Fortune Business Insights has profiled some of the prominent market players operating in the global ePharmacy market. They are as follows:

• DocMorris
• CVS Health Corporation
• Express Script Holding Company
• Walgreen Co.
• Optum Rx, Inc.
• Giant Eagle, Inc.
• Walmart Stores, Inc.
• Rowland Pharmacy
• The Kroger Co.
• Other players

Increasing Adoption of E-commerce Websites to Favor Growth in Asia Pacific

Geographically, the global ePharmacy market is grouped into Asia Pacific, North America, the Middle East and Africa, Europe, and Latin America. Out of these regions, North America is expected to remain in the leading position in the global ePharmacy market during the forecast period. The growth is attributed to the rapid shift of consumers towards online retailers from offline pharmacies. Also, increasing usage of smartphones and high speed of the Internet are expected to aid North America in gaining the highest global ePharmacy market share in the forthcoming years. Furthermore, a rise in geriatric population, increasing online orders, and growing adoption of online platforms will drive the market growth in this region.

Europe and Asia Pacific, on the other hand, are projected to exhibit significantly high CAGR during the forecast period. In Europe, numerous prominent market players have begun offering products at lucrative rates. This will positively impact growth of ePharmacy market in this region. Asia Pacific, on the other hand, has been witnessing higher adoption of e-commerce websites and increasing patient pool. Moreover, the healthcare infrastructure in this region is on the verge of becoming prosperous. All these factors are anticipated to fuel ePharmacy market growth in Asia Pacific in the coming years.

The global orthopedic implants market size is set to touch USD 64.0 billion by 2026, exhibiting a modest CAGR of 4.1% during the forecast period. Unprecedented rise in geriatric population across the globe to be the key growth driver of this market. According to the United States Census Bureau (USCB), the proportion of aged people to the total world population is steadily climbing. For example, in 2012, world population had reached 7 billion and the people aged 65 and above were 8% of this number or 562 million.

Browse Complete Report Details@   https://www.fortunebusinessinsights.com/industry-reports/orthopedic-implants-market-101659

Some of the key players in this market include:

• BioTek Instruments, Inc.
• Zimmer Biomet
• Integra LifeSciences Corporation
• DePuy Synthes Companies (Johnson & Johnson Services, Inc.)
• ArthroCare Corporation
• Medtronic
• CONMED Corporation
• Smith & Nephew

According to the report by Fortune Business Insights, titled “Orthopedic Implants Market Size, Share & Industry Analysis, By Product (Joint Reconstruction; Spinal Implants; Trauma Implants, Dental Implants; Orthobiologics, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026”, the market value stood at USD 46.5 billion in 2018. The report also incorporates a thorough analysis of the factors, upcoming trends, and dynamics that are likely to influence the growth trajectory of the market. The in-depth research contained in the report aims at equipping businesses with adequate information that will enable them to make informed decisions and strategies for the future.

Widespread Prevalence of Musculoskeletal Conditions to Spike Market Demand

Musculoskeletal conditions refer to disorders that adversely affect the locomotor system in the body, that is, bones, muscles, joints, ligaments, and tissues. Disorders related to these movements are increasing in prevalence, as stated by the World Health Organization (WHO). According to the WHO, between 20% and 33% of the world’s population is currently suffering from some painful and chronic musculoskeletal disease. The 2017 Global Burden of Disease Report revealed that musculoskeletal conditions were the second leading contributor to global disability, accounting for about 16% of all years with disability in an individual’s life. Given the economic costs associated with these disorders, the need to prevent them is stronger than ever today, which augurs well for the market as it will spur innovation among players in the forecast period.

New Product Launches to Intensify Market Competition

Key players are looking to gain an edge in the competition through development and launch of new products. For instance, in September 2019, Zimmer Biomet, after receiving FDA approval, commercially released its customizable revision knee replacement device called Persona Revision Knee System for patients in the US. Some other players are engaging in sprucing up their research capacities through commissioning of trials and studies. For example, in September 2019, Medtronic’s clinical trial for testing its spine correction surgical procedure, Infuse Bone Graft in Transforaminal Lumbar Interbody Fusion (TLIF), was green lit by the FDA.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/blog/top-10-telemedicine-companies-2020-10077

https://www.fortunebusinessinsights.com/blog/telemedicine-in-the-healthcare-industry-9966

The rising prevalence of unwanted pregnancies is boosting the global contraceptive drugs market. In a report, titled “Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025” Fortune Business Insights identifies various factors enabling growth in the market.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contraceptive-drugs-market-100063

According to the report, the global contraceptive drugs market is anticipated to rise at 5.8% CAGR and reach a value of US$ 20,200.5 Mn by 2025 from US$ 13,097.7 Mn in 2017. Remarkably improving access to contraceptive pills around the world is a key factor propelling growth in this market.

Rising Abortion Rates to Create Demand for Contraceptive Drugs

Under the Affordable Care Act (ACA) in the U.S., oral contraceptive pills are given free of cost to women in the U.S. Such regulations favor the growth of the contraceptive drugs market. Increasing government initiatives to reduce infant mortality due to early pregnancies will increase the demand for oral contraceptives. Contraceptive drugs not only help to control unwanted pregnancies but also reduce the number of abortion and complications associated with the procedure worldwide. As per the World Health Organization, there is an estimated 40 to 50 million abortions every year, corresponding to an approximate of 125,000 abortions per day. To avoid unwanted and unplanned pregnancies, an increasing number of women are opting for contraceptive drugs. This will in turn augment growth in the global market.

Contrary to this, the market for contraceptive drugs may face challenges posed by religious, ethical, and social barriers especially in more conservative regions. Social taboos often discourage the use of contraceptive drugs among women, subsequently adversely impacting the overall market.

Government Initiatives to Promote Use of Contraceptive Medicines

Geographically, North America held dominance in the global contraceptive drugs market owing to the presence of leading players in the region. This, accompanied with easy availability of contraceptive drugs, has catapulted North America to the fore of the global market. However, Asia Pacific is most likely to emerge as the fastest growing region. This is owing to government initiatives adopted across emerging nations of this region. These initiatives are intended at promoting the use of contraceptive medicines as a convenient way of preventing unwanted pregnancy.

According to Fortune Business Insights, the global contraceptive drugs market has a highly fragmented vendor landscape. This is because of the presence of both regional and international players. Major players are focusing on expanding their footprint across the world to gain a strong foothold in the market. Manufacturers are also putting efforts to improve their product visibility especially in developing economies with new marketing strategies. This is likely to make the competition fiercer as manufacturers are investing huge sums into research and development.

The global hereditary angioedema treatment market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017. The global market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164

some of the key players in the global Hereditary Angioedema Treatment Market:

• BIOCRYST PHARMACEUTICALS INC.
• Ionis Pharmaceuticals Inc.
• Attune Pharmaceuticals
• Arrowhead Pharmaceuticals Inc.
• Adverum

According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute the expansion of the hereditary angioedema treatment market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, increasing number of product innovations in the region backed by high presence of hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the hereditary angioedema treatment market.

C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period

In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.

Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.

Shire, CSL Behring, and Pharming Group NV to Lead the Global Market

The global hereditary angioedema treatment market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.

More Trending Topics from Fortune Business Insights:

https://www.fortunebusinessinsights.com/blog/wearable-medical-devices-market-9247

https://www.fortunebusinessinsights.com/blog/advanced-wound-care-market-9043